T1D treatment is a challenge, since imperfect, exogenous insulin administration aims to mimic (inexistent) endogenous insulin production, to keep glucose concentrations within a safe range, avoiding hyper- and hypoglycemia (high and low blood glucose levels, respectively). This evidence concerns the gene INS and type 1 diabetes mellitus.